Category: Stock Market

Shares in Mesoblast Ltd (ASX: MSB) are inching higher today and now trade around 3% in the green at $1.13.

Mesoblast shares have struggled of late, down 19% since trading restarted back in January, and down almost 53% in the past 12 months.

Today, Mesoblast informed the market that a new member has joined its board. Whilst the update isn’t market-sensitive in any way, it’s still integral to the company’s growth narrative.

What did Mesoblast announce?

The company advised that Dr Philip R. Krause, M.D. has joined its board of directors. Dr Krause is currently Chair of the World Health Organization COVID Vaccines Research Expert Group.

Mesoblast notes that “most recently he shared responsibility for regulatory authorizations of COVID-19 vaccines in the US.”

For the past decade, the company says that Dr Krause was Deputy Director, Office of Vaccines Research and Review (OVRR) at the US Food and Drug Administration’s (FDA) Center for Biologics Evaluation and Research (CBER).

Dr Krause said that he had followed Mesoblast’s story over the years and that he is looking forward to helping in successfully launching its products, that are “cutting-edge technology.”

“I have followed Mesoblast’s development programs closely and am very much looking forward to help guide the company as it brings its lead products to the market,” he remarked.

“I believe I can make a substantial contribution at this very important time in the company’s transition towards commercialisation”.

Meanwhile, Mesoblast CEO, Dr Silvu Istecu highlighted how pleased the company was in having Dr Krause on board, given his key expertise of the FDA and US markets.

“We are delighted to have Dr Krause join our board,” Istecu noted.

“The biologics development and regulatory expertise that he brings will be invaluable in our ongoing FDA interactions on our lead and follow-on product candidates,” he concluded.

Mesoblast has been under considerable pressure from short sellers lately, regularly finding itself on the daily 10 most shorted ASX shares list these past few weeks.

Jefferies has Mesoblast rated as a hold and values the company at $1.25 per share, in line with the consensus price target.

The consensus price target on Mesoblast shares has crept down from $6.50 in September 2020 alongside the stock price, which is now trading back around 5-year lows.

The post Here’s why the Mesoblast (ASX:MSB) share price is climbing today appeared first on The Motley Fool Australia.

More reading

• These are the 10 most shorted ASX shares
• These are the 10 most shorted ASX shares
• These were the best performing ASX 200 shares last week
• ASX 200 (ASX:XJO) midday update: Block falls, Nickel Mines jumps
• Mesoblast (ASX:MSB) share price rebounds 15%, what’s been happening?

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/MKdfCLN

The McPherson’s Ltd (ASX: MCP) share price is having a very strong day.

In morning trade, the health, wellness and beauty products company’s shares are up almost 15% to $1.02.

Why is the McPherson’s share price surging higher?

The catalyst for the rise in the McPherson’s share price has been the announcement of an agreement with pharmacy giant Chemist Warehouse Group.

According to the release, the two parties have agreed to establish a unique strategic alliance which has been structured to deliver material commercial and operational benefits to McPherson’s.

As part of the agreement, McPherson’s will be appointed as Chemist Warehouse’s exclusive long-term distributor of a select portfolio of Chemist Warehouse-owned or controlled health and beauty brands outside of the Chemist Warehouse Network in Australia and New Zealand.

The range, which includes Wagner Vitamins, Wagner Body Science, Bondi Protein, Foster Grant, INC and Microgenics, will be made available to all customers within the McPherson’s distribution network for an initial term of five-years commencing on 1 July 2022.

In addition, Chemist Warehouse will increase the portfolio of McPherson’s brands it currently ranges in Australia and New Zealand, to include Moosehead, Maseur, Fusion Health, Stratton, Sugar Baby and Happy Flora. The pharmacy giant will also recognise McPherson’s as a preferred supplier, allowing the company to enjoy the benefits of that status.

What’s the catch?

Chemist Warehouse isn’t doing this out of generosity. It will come at a cost to McPherson’s.

McPherson’s is essentially giving away almost 10% of the company to Chemist Warehouse in exchange for these agreements.

The release notes that the company will issue approximately 14.1 million McPherson’s shares to Chemist Warehouse on 1 July 2022, making the pharmacy chain a substantial shareholder with an interest of 9.9% on a fully diluted basis.

Despite the dilution caused by the material share issue, management expects the agreement to be earnings per share accretive in FY 2023. This is based on agreed sales targets.

Time will tell if that is the case.

The post McPherson’s (ASX:MCP) share price leaps 15% on Chemist Warehouse deal appeared first on The Motley Fool Australia.

More reading

• Janus Henderson (ASX:JHG) share price falls following new CEO appointment
• Incannex (ASX:IHL) share price slips on acquisition news
• Is a dividend boost on the cards for Bluescope (ASX:BSL) shares in FY22?
• Why is the Zip share price getting smashed so much more than other BNPL stocks in 2022?
• Own Telstra shares? Here’s how the telco plans to use drones to create carbon credits

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/e7aSwRQ

The Janus Henderson Group PLC (ASX: JHG) share price is in the red today.

Shares in the global fund manager closed at $47.62 yesterday and are currently trading for $45.89.

That puts the Janus Henderson share price down 3.6% in morning trade.

This comes as the company revealed who will be replacing Dick Weil as the new chief executive officer. Weil will be retiring from that position on 31 March.

Who will be taking over as CEO?

This morning, Janus Henderson reported that Ali Dibadj will take the reins as the new CEO, commencing no later than 27 June.

The Harvard educated 46-year-old previously served as chief financial officer and head of strategy at global asset manager, AllianceBernstein Holding.

Commenting on the appointment, Janus Henderson chairman Richard Gillingwater said:

As part of our CEO transition planning, we conducted an extensive internal and external search to identify an executive who both understands our business and has the necessary strategic expertise to help drive the firm’s next phase of growth for the benefit of our clients and shareholders. The Board is confident that Ali is the ideal choice to lead this great company into its next phase of growth and value creation.

Saying he was delighted with the appointment, Dibadj added:

I have long admired Janus Henderson’s commitment to deliver for its clients with investment and servicing excellence. The executive team, the Board, and I look forward to identifying, expediting, and capturing growth and innovation that creates value for our clients, employees, shareholders, communities, and all stakeholders.

Roger Thompson, Janus Henderson’s CFO, will step in as Interim CEO until Dibadj commences.

The company expects that Dibadj will also join the Board.

Janus Henderson share price snapshot

The Janus Henderson share price has struggled this year, down 21.2% since the opening bell on 4 January.

By comparison, the S&P/ASX 200 Index (ASX: XJO) is down 3% year-to-date.

The post Janus Henderson (ASX:JHG) share price falls following new CEO appointment appeared first on The Motley Fool Australia.

More reading

• Incannex (ASX:IHL) share price slips on acquisition news
• Is a dividend boost on the cards for Bluescope (ASX:BSL) shares in FY22?
• Why is the Zip share price getting smashed so much more than other BNPL stocks in 2022?
• Own Telstra shares? Here’s how the telco plans to use drones to create carbon credits
• NAB share price lower despite new $2.5bn buyback

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/h4ri8wp

The Incannex Healthcare Ltd (ASX: IHL) share price is having a tough time this morning. It sunk 7% from the open before recovering most of its losses and is now 0.71% in the red at 69.5 cents.

Investors are pushing Incannex shares lower after the company announced an acquisition deal.

Despite its shares taking a hit today, the medicinal cannabis company is still in the green across all major time frames, having climbed more than 235% in the past year.

What’s impacting the Incannex share price?

The Incannex share price is slipping after the company advised it had executed a term sheet to wholly acquire APIRx Pharmaceutical USA, LLC on a proposed all-scrip transaction price of US$93.3 million.

Incannex says APIRx is “an innovative biotechnology company focused on research, development, and production of prescription pharmaceutical cannabinoid medicines”.

It has 22 active clinical and preclinical research and development projects utilising its own proprietary technologies, the company added.

For Incannex, the acquisition is set to diversify its portfolio and give the company exposure to a wider array of markets, from pain to dementia to addiction disorders, just to name a few.

As a result, the company claims it now has an expanded total addressable market (TAM) of more than US$400 billion annually.

APIRx can also vote to have one board member designated to Incannex’s board after the transaction is completed.

Speaking on the proposed acquisition that might be affecting the Incannex share price today, CEO Joel Latham said:

We believe that bringing together Incannex and APIRx will bolster our position as a leader in the medicinal cannabinoid sector and will further set IHL apart from other players in the industry.

With sizeable addressable markets and intellectual property spanning a multitude of unmet medical needs, we’re positioning Incannex to be a significant player in the pharmaceutical sectors of the future. I’m excited by this acquisition opportunity on multiple fronts and look forward to working with the APIRx team to deliver on our vision of providing treatments which will make genuine differences to the lives of millions of people.

What’s next?

All the necessary steps are underway to get the transaction underway, but shareholder approval is needed first.

The company will hold an extraordinary general meeting to discuss the transaction and attempt to garner shareholder support.

Incannex will update the market on when this meeting will take place. It also provided some high-level cost estimates.

“Incannex anticipates budgeting approximately A$5.0 million of expenditure on the APIRx product suite in the first 12 months,” it said.

“However, the budget may be re-assessed to up to A$10 million following the conclusion, in April, of the Loyalty Option Offer, that could raise up to approximately A$28 million in development capital for the company.”

The Incannex share price is up 19% in the past month of trade and has climbed 9% this year to date.

The post Incannex (ASX:IHL) share price slips on acquisition news appeared first on The Motley Fool Australia.

More reading

• Here’s why the Incannex (ASX:IHL) share price is on ice today
• The Incannex (ASX:IHX) share price is up a whopping 50% in a week. What’s the deal?
• What’s going on with the Incannex (ASX:IHL) share price today?

The author has no positions in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/tvqh8yz

Shares in BlueScope Steel Ltd (ASX: BSL) are performing well lately and have charged 5% into the green over the past month.

On the last check, the Bluscope share price was fetching $20.56 apiece, having finished less than 1% in the red on Thursday.

As commodity baskets soared to record highs in 2021, Aussie miners have been returning cash to shareholders in droves by way of dividends and/or share buybacks.

Analysts at JP Morgan are constructive on Bluescope and reckon FY22 could be a year that sees considerable total shareholder return for those patient enough to stick with the company.

Still generating mammoth free cash flow

JP Morgan analysts note that steel prices have begun to catch up to input costs, with coking coal up around 60% at the time of its report whilst pig iron and iron ore were up 33% and 10% respectively.

The impulse caught up to steel prices in the US and Europe after a delayed response, with steel rebar climbing around 5% in the past month and over 18% since November.

This gain should feed cash down through Bluescope’s P&L, JP Morgan says, resulting in huge amounts of free cash flow (FCF) generation that could be redistributed back to shareholders.

“Despite declining from recent highs, spot spreads are still generating a strong 18% FCF yield for BSL from FY23 onwards, and spot earnings are still within the BBG consensus range,” it said.

“This highlights that despite strong cost inflation, BSL remainshighly FCF generative”.

FCF yield is a ratio that highlights a company’s ability to meet its financial obligations, but also its ability to support dividend growth, and other capital budgeting decisions.

The higher the yield, the greater prospect for Bluescope to reward its shareholders with a consistent stream of income via dividends.

In fact, that’s one thing JP Morgan likes in Bluescope’s investment debate – the fact it has “a shareholder return focus” in its mantra.

The steel giant is one of the broker’s favourite picks in FY22, backed by robust fundamentals and high prospects for outsized return.

“We continue to rate BSL as one of our preferred stocks under coverage, based on its valuation support, growth outlook, ongoing capital management, balance sheet strength, and backdrop of strong demand conditions,” it mentioned.

“Over time, we expect the company to grow domestic volumes in Australia, which should improve margins, while the North Star expansion also offers potential growth”.

With the prospects of a FCF yield in the high teens for FY22, JP Morgan projects Bluescope to deliver a dividend of 50 cents per share, followed by another 50 cent payment in FY23 and then again in FY24.

It also values the company at $25 per share whilst urging its clients to buy up shares at the current prices. Currently, the Bluescope share price is trading below the consensus valuation of $23.50, a spread of roughly $3 per share at the time of writing.

Bluescope share price snapshot

In the last 12 months, the Bluescope share price has climbed 10%, but it has slipped into the red since trading restarted in January.

During the previous month of trade, shares have picked back up and are now trading 5% in the green.

The post Is a 50c dividend on the cards for Bluescope (ASX:BSL) in FY22? appeared first on The Motley Fool Australia.

More reading

• These were the worst performing ASX 200 shares last week
• BlueScope Steel (ASX:BSL) share price sinks 9%
• ASX 200 (ASX:XJO) midday update: CSL and St Barbara charge higher

Motley Fool contributor Zach Bristow has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/weTl2fJ

The Zip Co Ltd (ASX: Z1P) share price is suffering this year, falling more than its fellow ASX-listed buy now, pay later (BNPL) peers.

And the past 30 days have seen that gap widen. Australia’s biggest BNPL stock has seen its value tumble by around 24% since this time last month. The Zip share price is currently down 3.95% today at $1.58.

For context, the second worst-performing ASX BNPL share is Sezzle Inc (ASX: SZL). Its stock has slipped around 7% over the last month.

Let’s take a look at what might be dragging on the Zip share price lately.

What’s behind the ZIP share price’s recent tumble?

Zip’s stock has tumbled 64% since the start of 2022.

That sees it taking the rear among its BNPL peers, of which Humm Group Ltd (ASX: HUM) has come out as one of the best performers. It has fallen just 12.5% in 2022.

However, the Zip share price has really underperformed over the last month, despite the announcement of a major acquisition.

As most market watchers will be aware, Zip and Sezzle are planning to come together in an all-scrip acquisition by the September quarter, subject to approvals.

Brokers’ mixed opinions regarding the transaction might have weighed on the BNPL provider’s stock lately.

Additionally, Zip’s recent $148.7 million capital raise and the release of its half-year results might have further dampened market enthusiasm for the company’s share price.

Zip officially released its half-year results late last month, detailing an 89% increase in revenue and a 92% increase in transaction volumes.

However, rising costs (the company’s cost of sales increased 192.5% last half) pushed Zip’s gross profits 23.2% lower.

Zip also offered 78.3 million new shares for $1.90 apiece as part of its recent institutional placement. At the time, the offer price represented a 14% discount to Zip’s stock’s previous closing price.

Finally, Zip is currently undergoing a share purchase plan, offering eligible shareholders the option to buy up to $30,000 worth of shares.

Under the plan, each new share will cost participating investors either $1.90 or a 2% discount on the Zip share price’s five-day volume-weighted average price for the period ending 1 April, whichever is lesser.

All that is likely weighing on the BNPL giant’s stock and might be causing it to underperform its peers.

The post Why is the Zip share price getting smashed so much more than other BNPL stocks in 2022? appeared first on The Motley Fool Australia.

More reading

• Leading the pack! ASX tech shares storm higher on Wednesday
• ASX 200 (ASX:XJO) midday update: Block and Zip jump, Fisher & Paykel Healthcare sinks
• From over $12 to $1.53 in little more than a year, why it may not be all bad news for the Zip share price
• Rollercoaster! Zip share price pops then drops
• 2 leading ASX 200 shares to watch as fundies rebalance portfolios

Motley Fool contributor Brooke Cooper has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended ZIPCOLTD FPO. The Motley Fool Australia has recommended Humm Group Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/dMiEsa8

Telstra Corporation Ltd (ASX: TLS) is taking a novel approach at meeting its carbon reduction emissions. One that includes plans for a fleet of tree tending drones.

If you own Telstra shares, you’ll own part of that fleet.

So, what exactly is the S&P/ASX 200 Index (ASX: XJO) telecom giant planning?

How is the telco planning to create carbon credits?

As reported by The Australian Financial Review, Telstra intends to plant 158,000 indigenous trees and shrubs across 240,000 hectares of land in northern New South Wales.

The project will employ drones to plant the seeds and monitor tree health. It’s estimated that the trees will pull some 160,000 tonnes of CO2 from the air over the next 25 years.

The land in question, according to Telstra, isn’t agricultural. Rather it’s land that needs repair and will be returned to its natural state.

As for the reasoning behind the company’s plans, Telstra’s CEO, Andrew Penn said that the price of carbon credits “is quite volatile” and they’re “increasingly difficult to come by”.

According to Penn:

Rather than just shop around, what I said to the team is: ‘Well, why is that the case? Why is that a problem?’ And, of course, part of the problem is we don’t have enough carbon farming projects to, basically, create those carbon credits.

And the telco’s futuristic project isn’t limited to seed planting drones.

“Other technologies we intend to explore include the use of robotics and artificial intelligence to improve pest and weed management,” Penn said. “And drones and sensors to monitor tree health and calculate the carbon stored in trees.”

Penn said Telstra’s networks, which support Australia’s booming digital economy, require a lot of electricity to run.

According to Penn (quoted by the AFR):

That’s driving more and more consumption, which then requires energy to run. So this is part of that overall mix of how we support development of carbon credits but also reduce our absolute [emissions] output at the same time.

How have Telstra shares been tracking?

Telstra shares, up 0.1% in early trade today, have been trailing the benchmark in 2022.

Year-to-date Telstra shares are down 7.5%, compared to a loss of 3% posted by the ASX 200.

The post Own Telstra shares? Here’s how the telco plans to use drones to create carbon credits appeared first on The Motley Fool Australia.

More reading

• Is the Telstra share price a buying opportunity after sliding 7% in 2022?
• 2 high-yield ASX dividend shares that brokers love
• 2 ASX 200 dividend shares analysts are urging income investors to buy
• These ASX 200 shares are topping the volume charts on Friday
• These 3 ASX 200 shares are topping the volume charts this Thursday

The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia owns and has recommended Telstra Corporation Limited. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/OgHQlsr

The National Australia Bank Ltd (ASX: NAB) share price is falling on Thursday.

In morning trade, the banking giant’s shares are down 0.75% to $31.49 amid broad weakness in the sector.

This is despite NAB making a positive announcement prior to the market open.

What did NAB announce?

This morning NAB announced that it has now completed its $2.5 billion on-market buy-back, which resulted in a total of 86,925,469 ordinary shares being bought back by the banking giant.

However, it is not settling for that. Thanks to its strong capital position, the bank plans to launch another new on-market buy-back.

According to the release, NAB intends to commence a further on-market buy-back of up to $2.5 billion, bringing the total potential combined size to $5 billion. Subject to market conditions, NAB expects to commence the further buy-back following its half year results release on 5 May 2022.

The release notes that the new buy-back will allow NAB to continue managing its Common Equity Tier 1 (CET1) capital ratio towards its target range of 10.75% to 11.25% over time.

NAB’s Group Chief Executive Officer, Ross McEwan, explained: “Our capital management strategy reflects the importance of maintaining a strong balance sheet through the cycle while allowing us to continue to support growth and deliver improved shareholder returns. The further $2.5 billion on-market buy-back announced today supports our ambition to reduce share count and increase sustainable ROE benefits for our shareholders.”

What impact will this have on its capital position?

NAB advised that it continues to operate well above APRA’s Unquestionably Strong benchmark of 10.50%, with a reported CET1 capital ratio of 12.4% as of 31 December 2021.

The further $2.5 billion on-market buy-back will reduce its CET1 capital ratio by approximately 58 basis points. Combined with other adjustments such as the Citi acquisition, on a pro forma basis, NAB’s CET1 capital ratio would be 11.3%.

This remains comfortably ahead of APRA’s benchmark, which potentially provides scope for even more shareholder returns in the future.

The post NAB share price lower despite new $2.5bn buyback appeared first on The Motley Fool Australia.

More reading

• NAB, ANZ and CBA shares in focus as top broker tips extra $5b share buyback
• Banking gains! NAB share price hits yet another 52-week high
• The National Australia Bank (ASX:NAB) share price target upgraded by a top broker
• Cha-ching! The NAB share price just hit a multi-year high
• Fundie tells why two-thirds of all dividends come from just 7 ASX shares. Guess which ones?

Motley Fool contributor James Mickleboro has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has no position in any of the stocks mentioned. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/7g0Fpcm

The Cochlear Limited (ASX: COH) share price has recovered most of its lost ground over the past couple of years. It’s almost back to where it was before the COVID-19 pandemic hit the world.

Cochlear describes itself as a leader in implantable hearing devices that help to restore hearing and connect people to a world of sound.

Is the Cochlear share price going to keep rising?

No one has a crystal ball that can say exactly what share prices are going to do next.

However, analysts can estimate what they think a business is worth and the direction a share price is headed.

Citi is one of the latest brokers to give an updated opinion on the business.

The broker has a buy rating on Cochlear shares with a price target of $235. That implies a possible upside of around 5% over the next 12 months.

Citi has noticed the recent ASX share market volatility. The prospect of interest rates going up as well as the Russian invasion of Ukraine has caused a pullback on the Cochlear share price.

However, the reason for optimism about the ASX healthcare share is COVID-19 impacts subsiding could mean a boost for Cochlear.

Analysts at Morgans also expect the company’s positive performance over the last 12 months to continue in coming years. Morgans has an add rating and a $233.20 target on the Cochlear share price.

Cochlear’s recent growth and outlook

In the recent FY22 half-year result, the company reported that Cochlear implant units increased by 7% to 18,598 with sales revenue growing 10% to $815.3 million. Cochlear said there was strong demand for sound processor upgrades and new acoustic implant products.

However, Cochlear implant revenue continued to experience variability in performance across countries with intermittent COVID-related restrictions reducing operating theatre capacity.

Developed market volumes were ahead of pre-COVID levels despite a modest decline in the half, and its market share position remained “strong”.

Cochlear reported that underlying net profit after tax (NPAT) grew by 26% to $157.5 million.

In terms of the outlook, the company said the underlying net profit guidance range was still $265 million to $285 million, which would represent an increase of between 13% and 22% on FY21. That guidance now includes cloud computing expenses and anticipates continuing COVID-19 impacts for the rest of the financial year.

The second-half trading was tracking in line with the first half. Elective surgery restrictions are hampering some activity. Operating theatre capacity is also being affected by hospital staffing shortages. It’s expecting a lower rate of growth for Cochlear implants for the financial year than originally forecast.

However, despite the ongoing disruption to surgeries caused by COVID, Cochlear continues “to be confident of the resilience” of its business over the longer term.

Long-term opportunity

The Cochlear share price could be influenced by the company’s ability to capture the market opportunity ahead.

The World Health Organisation estimates there are more than 60 million people worldwide who have severe or higher hearing loss. Cochlear says there is a significant, unmet, and addressable clinical need for implantable hearing solutions, with less than 5% market penetration.

It benefits from a growing annuity income stream from the servicing of the expanding recipient base.

Cochlear share price snapshot

The Cochlear share price is down 1.68% at $219.56 in early trading today. However, it is up around 5% over the past year and more than 3% this year to date.

It is now trading at similar levels to what it was before the COVID-19 pandemic took hold in March 2020.

The post The Cochlear (ASX:COH) share price has bounced back from the pandemic. Are there more gains to come? appeared first on The Motley Fool Australia.

More reading

• Cheap ASX share better than Woolworths (ASX:WOW)– and it pays dividends
• The next ASX share ready to join the 20-bagger club: expert
• Analysts name 2 ASX 200 healthcare shares to bring your portfolio back to life
• Are Cochlear (ASX:COH) shares worth buying for dividends?
• 2 of the best ASX healthcare shares to buy now, according to analysts

Motley Fool contributor Tristan Harrison has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Cochlear Ltd. The Motley Fool Australia has recommended Cochlear Ltd. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson.

from The Motley Fool Australia https://ift.tt/LKB0Ric

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

What happened

A little over two weeks after it announced receipt of “conditional approval” to open its $5.5 billion gigafactory in the town of Grünheide near Berlin, Tesla (NASDAQ: TSLA) officially announced the factory’s opening on Tuesday. Reports say that CEO Elon Musk literally danced in joy at the opening.  

Investors are pretty happy, too, because today, Tesla stock is up 3.3% as of 11:05 a.m. ET. 

So what

Why is this such a big deal for Tesla? As The Wall Street Journal explained yesterday, Tesla plans to grow its Berlin gigafactory to the point where it will be able to produce 500,000 cars per year — but that’s just one part of the good news.  

By building cars in Europe, Tesla will be able to avoid both the cost of shipping cars to Europe from plants in the U.S. and China as well as import tariffs — two factors that should lower the price of its cars, encourage more sales in Europe, and make Tesla better able to compete with local car rivals such as BMW and Volkswagen. As Musk said in a statement, “[It] makes a huge difference to capital efficiency to localize production within a continent.”

Additionally, the plant’s location in Germany will make it easier for Tesla “to tailor vehicles to local tastes,” notes the Journal, which should also help with sales.

Now what

Not that Tesla necessarily needs help. As the Journal points out, sales of electric vehicles (EVs) and plug-in hybrids in Europe nearly doubled as a percentage of overall sales last year, to 18%. Tesla’s biggest challenge at this point will be ramping up production to satisfy all the demand for EVs in Europe.

Granted, as the CEO pointed out last night, “The start of production is nice, but volume production is the hard part.” But with Tesla targeting 5,000 to 10,000 cars per week produced by the end of this year, it seems the new German plant will be at least 50% operational — and potentially even fully operational — in just eight more months, maxing out its 500,000 car-per-year capacity.  

Simply put: Tesla’s off to the races in Germany. No wonder investors are excited. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

The post Why Tesla stock went up again appeared first on The Motley Fool Australia.

More reading

• Full charge ahead: The Pilbara Minerals (ASX:PLS) share price lifts another 4% today
• Elon Musk wants Tesla to be much, much bigger
• Why Tesla shares are up ahead of ‘Delivery day’
• Why Tesla stock keeps driving higher
• Why did Tesla stock pop today?

Rich Smith has no position in any of the stocks mentioned. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. owns and has recommended Tesla. The Motley Fool Australia’s parent company Motley Fool Holdings Inc. has recommended BMW. The Motley Fool Australia has no position in any of the stocks mentioned. The Motley Fool has a disclosure policy. This article contains general investment advice only (under AFSL 400691). Authorised by Bruce Jackson. 

This article was originally published on Fool.com. All figures quoted in US dollars unless otherwise stated.

from The Motley Fool Australia https://ift.tt/Vmodc1q